Larimar started at buy by Truist on Friedreich's ataxia drug
Truist has initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich’s ...
Indiatimes24m
RIL Share Price
Bonus Oct 28, 2024 Oct 28, 2024 Sep 05, 2024 Bonus Ratio: 1 share(s) for every 1 shares held Rights May 13, 2020 May 14, 2020 Apr 30, 2020 Rights ratio: 1 share for every 15 held at a price of Rs 1257 ...